| Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (NCT02123511) | Mayo Clinic | 2014-04-01 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy (NCT01806675) | Sanjiv Sam Gambhir | 2013-03-04 |
| Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer (NCT01254734) | City of Hope Medical Center | 2011-04-01 |
| L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer (NCT01155609) | University of Washington | 2010-09-01 |
| Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer (NCT01637194) | Fox Chase Cancer Center | 2008-11-01 |
| Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck (NCT01473784) | Ohio State University Comprehensive Cancer Center | 2007-12-03 |
| Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer (NCT00492089) | National Cancer Institute (NCI) | 2007-06-01 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (NCT00397384) | National Cancer Institute (NCI) | 2007-01-01 |
| Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer (NCT00470496) | Roswell Park Cancer Institute | 2006-10-19 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (NCT00101348) | National Cancer Institute (NCI) | 2005-01-01 |
| Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers (NCT00095563) | National Cancer Institute (NCI) | 2004-09-01 |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors (NCT00089362) | National Cancer Institute (NCI) | 2004-07-01 |
| Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck (NCT00077428) | National Cancer Institute (NCI) | 2004-06-01 |
| Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (NCT00068497) | National Cancer Institute (NCI) | 2003-08-01 |
| 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (NCT00031681) | National Cancer Institute (NCI) | 2001-12-01 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (NCT00030498) | National Cancer Institute (NCI) | 2001-12-01 |
| Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer (NCT00023959) | National Cancer Institute (NCI) | 2001-07-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |